Our core technology is our patented method for the isolation and cultivation of regenerative muscle stem cells.
This enables us to produce large high-purity populations of stem cells that we call PHSats: Primary Human Satellite cell derived muscle stem cells. In contrast to conventionally cultured muscle cells, PHSats retain the regenerative capacity of satellite cells.
From just a few grammes of tissue, more than 100 million pharmaceutical quality PHSats can be produced. In preclinical studies PHSats built new muscle tissue and repopulated the stem cell niche, thereby providing both short and long-term regenerative effects.
In patients with local muscle defects, this technology enables effective autologous treatment.